Fungal infections in HIV/AIDS

Andrew Harold Limper, Antoine Adenis, Thuy Le, Thomas S. Harrison

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS. Systemic infections are mainly with Pneumocystis jirovecii (pneumocystosis), Cryptococcus neoformans (cryptococcosis), Histoplasma capsulatum (histoplasmosis), and Talaromyces (Penicillium) marneffei (talaromycosis). The incidence of systemic fungal infections has decreased in people with HIV in high-income countries because of the widespread availability of antiretroviral drugs and early testing for HIV. However, in many areas with high HIV prevalence, patients present to care with advanced HIV infection and with a low CD4 cell count or re-present with persistent low CD4 cell counts because of poor adherence, resistance to antiretroviral drugs, or both. Affordable, rapid point-of-care diagnostic tests (as have been developed for cryptococcosis) are urgently needed for pneumocystosis, talaromycosis, and histoplasmosis. Additionally, antifungal drugs, including amphotericin B, liposomal amphotericin B, and flucytosine, need to be much more widely available. Such measures, together with continued international efforts in education and training in the management of fungal disease, have the potential to improve patient outcomes substantially.

Original languageEnglish (US)
JournalThe Lancet Infectious Diseases
DOIs
StateAccepted/In press - 2017

Fingerprint

Mycoses
Acquired Immunodeficiency Syndrome
HIV
Cryptococcosis
Histoplasmosis
Pneumocystis Pneumonia
CD4 Lymphocyte Count
Talaromyces
Point-of-Care Systems
Pharmaceutical Preparations
Histoplasma
Flucytosine
Pneumocystis carinii
Cryptococcus neoformans
Penicillium
Opportunistic Infections
Amphotericin B
Routine Diagnostic Tests
HIV Infections
Fungi

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Fungal infections in HIV/AIDS. / Limper, Andrew Harold; Adenis, Antoine; Le, Thuy; Harrison, Thomas S.

In: The Lancet Infectious Diseases, 2017.

Research output: Contribution to journalArticle

Limper, Andrew Harold ; Adenis, Antoine ; Le, Thuy ; Harrison, Thomas S. / Fungal infections in HIV/AIDS. In: The Lancet Infectious Diseases. 2017.
@article{590c4de73522460197505ff94fdd557d,
title = "Fungal infections in HIV/AIDS",
abstract = "Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS. Systemic infections are mainly with Pneumocystis jirovecii (pneumocystosis), Cryptococcus neoformans (cryptococcosis), Histoplasma capsulatum (histoplasmosis), and Talaromyces (Penicillium) marneffei (talaromycosis). The incidence of systemic fungal infections has decreased in people with HIV in high-income countries because of the widespread availability of antiretroviral drugs and early testing for HIV. However, in many areas with high HIV prevalence, patients present to care with advanced HIV infection and with a low CD4 cell count or re-present with persistent low CD4 cell counts because of poor adherence, resistance to antiretroviral drugs, or both. Affordable, rapid point-of-care diagnostic tests (as have been developed for cryptococcosis) are urgently needed for pneumocystosis, talaromycosis, and histoplasmosis. Additionally, antifungal drugs, including amphotericin B, liposomal amphotericin B, and flucytosine, need to be much more widely available. Such measures, together with continued international efforts in education and training in the management of fungal disease, have the potential to improve patient outcomes substantially.",
author = "Limper, {Andrew Harold} and Antoine Adenis and Thuy Le and Harrison, {Thomas S.}",
year = "2017",
doi = "10.1016/S1473-3099(17)30303-1",
language = "English (US)",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Fungal infections in HIV/AIDS

AU - Limper, Andrew Harold

AU - Adenis, Antoine

AU - Le, Thuy

AU - Harrison, Thomas S.

PY - 2017

Y1 - 2017

N2 - Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS. Systemic infections are mainly with Pneumocystis jirovecii (pneumocystosis), Cryptococcus neoformans (cryptococcosis), Histoplasma capsulatum (histoplasmosis), and Talaromyces (Penicillium) marneffei (talaromycosis). The incidence of systemic fungal infections has decreased in people with HIV in high-income countries because of the widespread availability of antiretroviral drugs and early testing for HIV. However, in many areas with high HIV prevalence, patients present to care with advanced HIV infection and with a low CD4 cell count or re-present with persistent low CD4 cell counts because of poor adherence, resistance to antiretroviral drugs, or both. Affordable, rapid point-of-care diagnostic tests (as have been developed for cryptococcosis) are urgently needed for pneumocystosis, talaromycosis, and histoplasmosis. Additionally, antifungal drugs, including amphotericin B, liposomal amphotericin B, and flucytosine, need to be much more widely available. Such measures, together with continued international efforts in education and training in the management of fungal disease, have the potential to improve patient outcomes substantially.

AB - Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS. Systemic infections are mainly with Pneumocystis jirovecii (pneumocystosis), Cryptococcus neoformans (cryptococcosis), Histoplasma capsulatum (histoplasmosis), and Talaromyces (Penicillium) marneffei (talaromycosis). The incidence of systemic fungal infections has decreased in people with HIV in high-income countries because of the widespread availability of antiretroviral drugs and early testing for HIV. However, in many areas with high HIV prevalence, patients present to care with advanced HIV infection and with a low CD4 cell count or re-present with persistent low CD4 cell counts because of poor adherence, resistance to antiretroviral drugs, or both. Affordable, rapid point-of-care diagnostic tests (as have been developed for cryptococcosis) are urgently needed for pneumocystosis, talaromycosis, and histoplasmosis. Additionally, antifungal drugs, including amphotericin B, liposomal amphotericin B, and flucytosine, need to be much more widely available. Such measures, together with continued international efforts in education and training in the management of fungal disease, have the potential to improve patient outcomes substantially.

UR - http://www.scopus.com/inward/record.url?scp=85026516472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026516472&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(17)30303-1

DO - 10.1016/S1473-3099(17)30303-1

M3 - Article

C2 - 28774701

AN - SCOPUS:85026516472

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

ER -